<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/389437</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389437v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;389437</article-id><article-id pub-id-type="other" hwp:sub-type="slug">389437</article-id><article-id pub-id-type="other" hwp:sub-type="tag">389437</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Genomics" hwp:journal="biorxiv"><subject>Genomics</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Identification and Ranking of Recurrent Neo-Epitopes in Cancer</article-title></title-group><author-notes hwp:id="author-notes-1"><corresp id="cor1" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1"><label>*</label>To whom correspondence should be addressed: <email hwp:id="email-1">dieter.beule@bihealth.de</email></corresp></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4369-0254</contrib-id><name name-style="western" hwp:sortable="Blanc Eric"><surname>Blanc</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0002-4369-0254"/></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Holtgrewe Manuel"><surname>Holtgrewe</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-2" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Dhamodaran Arunraj"><surname>Dhamodaran</surname><given-names>Arunraj</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Messerschmidt Clemens"><surname>Messerschmidt</surname><given-names>Clemens</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-3" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Willimsky Gerald"><surname>Willimsky</surname><given-names>Gerald</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Blankenstein Thomas"><surname>Blankenstein</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-2" hwp:rel-id="aff-2">2</xref><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-2" hwp:rel-id="aff-3">3</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-2" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Beule Dieter"><surname>Beule</surname><given-names>Dieter</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-3" hwp:rel-id="aff-3">3</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">*</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4"><label>1</label><institution hwp:id="institution-1">Core Unit Bioinformatics, Berlin Institute of Health</institution>, Berlin, <country>Germany</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1 xref-aff-2-2"><label>2</label><institution hwp:id="institution-2">Institute of Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health</institution>, Berlin, <country>Germany</country></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1 xref-aff-3-2 xref-aff-3-3"><label>3</label><institution hwp:id="institution-3">Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)</institution>, Berlin, <country>Germany</country></aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1 xref-aff-4-2"><label>4</label><institution hwp:id="institution-4">Berlin Institute of Health</institution>, Berlin, <country>Germany</country></aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1 xref-aff-5-2 xref-aff-5-3"><label>5</label><institution hwp:id="institution-5">Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health</institution>, Berlin, <country>Germany</country></aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1"><label>6</label><institution hwp:id="institution-6">German Cancer Research Center (DKFZ)</institution>, Heidelberg, <country>Germany</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2018-08-10T07:03:21-07:00">
    <day>10</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-08-10T07:03:21-07:00">
    <day>10</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2018-08-10T07:10:55-07:00">
    <day>10</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-08-10T07:10:55-07:00">
    <day>10</day><month>8</month><year>2018</year>
  </pub-date><elocation-id>389437</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2018-08-10"><day>10</day><month>8</month><year>2018</year></date>
<date date-type="rev-recd" hwp:start="2018-08-10"><day>10</day><month>8</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-08-10"><day>10</day><month>8</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="license-1"><p hwp:id="p-1">This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></license></permissions><self-uri xlink:href="389437.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/389437v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="389437.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/389437v1/389437v1.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/389437v1/389437v1.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><p hwp:id="p-2">Neo-epitopes are emerging as attractive targets for cancer immunotherapy and new strategies for rapid identification of relevant candidates have become a priority. We propose a method for in silico selection of candidates which have a high potential for neo-antigen generation and are likely to appear in multiple patients. This is achieved by carefully screening 33 TCGA data sets for recurrent somatic amino acid exchanges and, for the 1,055 resulting recurrent variants, applying MHC class I binding prediction algorithms. A preliminary confirmation of epitope binding and recognition by CD8 T cells has been carried out for a couple of candidates in humanized mice. Recurrent neo-epitopes may be suitable to supplement existing personalized T cell treatment approaches with precision treatment options.</p></abstract><counts><page-count count="20"/></counts><custom-meta-wrap>
    <custom-meta hwp:id="custom-meta-1">
      <meta-name>has-earlier-version</meta-name>
      <meta-value>yes</meta-value>
    </custom-meta>
  </custom-meta-wrap></article-meta></front><body><sec id="s1" hwp:id="sec-1"><title hwp:id="title-2">Introduction</title><p hwp:id="p-3">Increasing evidence suggests that clinical efficacy of cancer immunotherapy is driven by T cell reactivity against neo-antigenes (<xref rid="c1" ref-type="bibr" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>, <xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref>, <xref rid="c3" ref-type="bibr" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref>, <xref rid="c4" ref-type="bibr" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">4</xref>). For tumors with no viral etiology these neo-antigenes are created either by aberrant expression of genes normally restricted to immuno-privileged tissues, or by tumor specific DNA alterations that result in the formation of novel protein sequences.</p><p hwp:id="p-4">While not yet fully understood, immune response to any mutated peptide sequence and recognition of tumor cells containing this peptide depends critically on the ability of the MHC class I complexes to bind to the mutated peptide in order to present it to a T cell (<xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref>). A variety of machine learning algorithms have been developed to determine the MHC binding in silico, see (<xref rid="c6" ref-type="bibr" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>) for review. Most methods are trained on Immune Epitope Database (IEDB) (<xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>) entries and use allele specific predictors for frequent alleles, while pan-methods are applied to extrapolate to less common alleles.</p><p hwp:id="p-5">With the advent of affordable short read sequencing comprehensive neo-antigen screening based on whole exome sequencing has become feasible and many cancer immune therapeutic approaches try to utilize detailed understanding of the neo-epitope spectrum to create additional or boost pre-existing T cell reactivity for therapeutic purposes (<xref rid="c8" ref-type="bibr" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>, <xref rid="c9" ref-type="bibr" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref>). However, in practice the selection and validation of the most promising neo-epitope candidates is a difficult and time-consuming task.</p><p hwp:id="p-6">By virtue of the underlying mutational processes, the genome architecture and accessibility as well as for functional reasons within the disease process, certain somatic mutations will be present in multiple patients while still being highly specific to the tumor (<xref rid="c10" ref-type="bibr" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref>, <xref rid="c11" ref-type="bibr" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref>). This might open the way to supplement existing personalized cancer immune treatments approaches with precision treatment options.</p><p hwp:id="p-7">Analysis of neo-epitope candidates has been carried out for selected highly recurrent mutations occurring in known cancer-related genes (<xref rid="c12" ref-type="bibr" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref>, <xref rid="c13" ref-type="bibr" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref>). Here we provide an unbiased, comprehensive study of neo-epitopes arising from recurrent mutations: we carefully screen large cohorts of cancer genomes for recurrent missense mutations, identify possible candidates for strongly binding neo-antigens in multiple HLA-1 alleles using MHC-I binding predictions, and finally rank these candidates according to the expected number of target patients. A couple of these candidates were tested for in-vivo activity.</p></sec><sec id="s2" hwp:id="sec-2"><title hwp:id="title-3">Results</title><sec id="s2a" hwp:id="sec-3"><title hwp:id="title-4">Recurrent Variants and Neo-Epitopes</title><p hwp:id="p-8">From the GDC repository (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref>), we have collected somatic variants for 33 TGCA studies. After removing patients without clinical meta-data, and studies with less than 100 patients, we have selected 1,384,531 high-confidence missense SNPs from 9,641 patients, see methods for details. Using this data, 1,055 variants are deemed recurrent (supplementary table 1), as they can be found in more than 1% of the patients in the respective study cohort. These recurrent variants correspond to 869 unique protein changes, as some appear in multiple cancer entities. 77 of the recurrent variants occur in at least 3% of their cohort (43 unique protein changes).</p><p hwp:id="p-9">From these 869 unique protein changes, we have generated neo-epitope candidates that are predicted to be strong MHC class I binders in at least one of the 11 frequent HLA-1 types that we considered for initial selection. 415 (48%) of them lead to a strong binder prediction. In total, there are 772 candidates that are recurrent in a cancer entity cohort, and predicted as binding for a considered HLA-1 type. These candidates are unique among all the 9-, 10- &amp; 11-mers containing the variant: the selection process retains only the peptide sequence with the lowest predicted IC50. <xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1</xref> and <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">table 1</xref> provide an overview of the variant selection and neo-epitope candidates generation processes, while supplementary table 2 lists all neo-epitopes (weak and strong predicted binders) after removing redundancy.</p><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389437v1/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1:</label><caption hwp:id="caption-1"><p hwp:id="p-10">Overview of the 33 TCGA studies used in this analysis: the studies displayed in italics have not been used for the determination of recurrent variants, as the number of patients is less than 100. The number of strong binders includes all occurrences of recurrent neo-epitopes, so a variant may be counted multiple times when it is predicted to be binding several HLA-1 types.</p></caption><graphic xlink:href="389437_tbl1" position="float" orientation="portrait" hwp:id="graphic-1"/></table-wrap><fig id="fig1" position="float" fig-type="figure" orientation="portrait" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389437v1/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1:</label><caption hwp:id="caption-2"><p hwp:id="p-11">(A) Overview of the recurrent neo-epitope candidates generation process: TCGA studies are selected for at least 100 donors with clinical annotations. For each of these studies, recurrent strongly supported missense Single-Nucleotide Variants are collected. Neo-epitopes binding to 11 HLA-1 types are predicted, redundancy is removed from that set (see B) and strong binders are retained. (B) Example of epitope redundancy: the 18 amino-acids long sequence surrounding recurrent variant GLRA3:S274L generates 7 binding neo-epitopes for the type HLA-A*02:01. Our pipeline retains only the strongest predicted binder for a given variant and HLA-1 type pair (the first, with an IC50 of 8.8 nM in the example). (C) Number of SNVs classified as Oncogenes or Tumor Suppressors by Vogelstein et al. (<xref rid="c20" ref-type="bibr" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref>), at various point of the variant selection and neo-epitope filtering process.</p></caption><graphic xlink:href="389437_fig1" position="float" orientation="portrait" hwp:id="graphic-2"/></fig><p hwp:id="p-12">Despite large differences between variant filtering protocols, there is notable overlap between variants deemed recurrent by the above process, and variants identified in the cancer hotspot datasets (<xref rid="c10" ref-type="bibr" hwp:id="xref-ref-10-2" hwp:rel-id="ref-10">10</xref>) (supplementary figure 1). This overlap is strongly dependent on how frequent those variants are observed: there are 54 common variants out of the 61 variants observed more than 10 times over the whole dataset (&gt;88%). Among the 819 retained variants (see methods), only 5 appear among the variants flagged as possible false positive by Chang et al. (&lt;1%).</p></sec><sec id="s2b" hwp:id="sec-4"><title hwp:id="title-5">Confirmation of known cancer neo-epitopes</title><p hwp:id="p-13">To validate our selection mechanism we aggregated two studies (<xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>, <xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref>) which collect reports of spontaneous CD8+ T-cell responses in cancer patients in whom the target epitopes were subsequently discovered. Both sets together (supplementary table 3) contain 37 epitopes, 35 of which could be mapped to an ENSEMBL transcript (33 unique genes). For 27 of these epitopes our pipeline predicted strong binding with the specific HLA-1 type reported in the corresponding wet-lab investigations. Another 5 epitopes where predicted as weak binders, some of the latter are also predicted to be strong binders in other HLA-1 types. Our pipeline classified 70% of a set of known tumor neo-antigens as strong binders and another 14% as weak binders. Therefore we may assume that these 70% provide a rough estimate of the sensitivity of the screening. However we expect sensitivity to vary widely for different HLA-1 types due to the different amount of training data and resulting limitation of prediction performance in less frequent HLA-1 types.</p><p hwp:id="p-14">4 out of 34 unique identifiable variants studied by van Buuren et al (<xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-2" hwp:rel-id="ref-16">16</xref>) and Fritsch (<xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-2" hwp:rel-id="ref-15">15</xref>) are found among our set of high confidence missense variants. CDK12:E928K occurs in one out of 530 Uterine Carcinoma donors, LPGAT1:D266N in one out of 985 Breast carcinoma donors, and CDK4:R24C occurs in 1 out of 467 of melanoma-patients. None of these epitopes have been assessed in our analysis, as their recurrence is below the 1% threshold. Only CTNNB1:S37F fulfills the 1% recurrence threshold (9 uterine carcinoma patients), and the peptide is predicted to be a strong binder for HLA-C*07:02. A longer peptide is predicted to be a strong binder for HLA-B*15:01.</p><p hwp:id="p-15">The CDK4:R24C peptide (sequence ACDPHSGHFV, see supplementary table 1) is not predicted to bind to HLA-A*02:01, even tough it leads to confirmed T cell response (<xref rid="c17" ref-type="bibr" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref>), and has been related to cutaneous malignant melanoma and hereditary cutaneous melanoma (<xref rid="c18" ref-type="bibr" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref>, <xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>). Therefore the list of recurrent amino acids exchanges for which no binding epitopes are predicted might still be a valuable resource for future research, see supplementary tables 1 (all recurrent variants) and 2 (includes candidates predicted as weak binders).</p></sec><sec id="s2c" hwp:id="sec-5"><title hwp:id="title-6">Enrichment in known cancer related genes</title><p hwp:id="p-16">We observe that recurrent neo-epitope candidates are substantially enriched in known cancer-related genes (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-2" hwp:rel-id="F1">figure 1C</xref>). Initially approximatively one percent of all observed variants are found in genes that have been described (<xref rid="c20" ref-type="bibr" hwp:id="xref-ref-20-2" hwp:rel-id="ref-20">20</xref>, <xref rid="c21" ref-type="bibr" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref>) as oncogenes or tumor suppressor genes. When recurrent unique protein changes are considered, the fraction of known oncogenes or tumor suppressor genes is substantially increased to 13% and 6.5% respectively. These fractions only marginally increase to 14% and 7% when only the unique protein changes leading to predicted strong binders for our 11 HLA-1 types are considered. Supplementary table 4 shows a similar enrichment of known cancer-related genes per cohort. We observe that the enrichment is stronger for oncogenes than for tumor suppressors. This might be expected, as activating mutations in oncogenes are mainly distributed on a few protein positions, while loss of function mutations in tumor suppressors are generally distributed more broadly along the protein sequence.</p><p hwp:id="p-17">It is interesting to observe that several of the highly prevalent neo-epitope candidates occur in genes that are involved in known immune escape mechanisms: RAC1:P29S is recurrent in study SKCM (melanoma), is predicted to lead to strong binding neo-epitopes for HLA-A*01:01 and HLA-A*02:01, and is reported to up-regulate PD-L1 in melanoma (<xref rid="c22" ref-type="bibr" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref>). CTNNB1:S33C is recurrent in studies LIHC (liver hepatocellular carcinoma) and UCEC (uterine corpus endometrial carcinoma), is predicted to lead to strong binding neo-epitopes for HLA-A*02:01, and has been shown to increase the expression of the Wnt-signalling pathway in hepatocellular carcinoma (<xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref>), leading to modulation of the immune response (<xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>) and ultimately to tumor immune escape (<xref rid="c25" ref-type="bibr" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref>). In a separate study, Cho et al (<xref rid="c26" ref-type="bibr" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">26</xref>) show that this mutation confers acquired resistance to the drug imatinib in metastatic melanoma. Finally, FLT3:D835Y recurrent in study LAML (acute myeloid leukemia), is predicted to lead to a strong binding neo-epitope for HLA-A*01:01, HLA-A*02:01 and HLA-C*06:02, and following Reiter et al. (<xref rid="c27" ref-type="bibr" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref>), Tyrosine Kinase Inhibitors promote the surface expression of the mutated FLT3, enhancing FLT3-directed immunotherapy options, as its surface expression is negatively correlated with proliferation.</p><p hwp:id="p-18">While the described mechanisms are probably sufficient to explain immune escape in tumor evolution, the candidates could nevertheless be viable targets for adoptive T cell therapy or TCR gene therapy.</p></sec><sec id="s2d" hwp:id="sec-6"><title hwp:id="title-7">Confirmation of MHC binding and T cell reactivity</title><p hwp:id="p-19">In order to further test predicted epitopes for recognition in vivo we utilized transgenic mice that harbor the human TCRαβ gene loci, a chimeric HLA-A2 gene and are deficient for mouse TCRαβ and mouse MHC I genes (termed ABabDII). These mice have been shown to express a diverse human TCR repertoire (<xref rid="c28" ref-type="bibr" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">28</xref>, <xref rid="c29" ref-type="bibr" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">29</xref>) and thus mimic human T cell response. Validation was carried out for candidate neo-epitopes RAC1:P29S &amp; TRRAP:S722F (<xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-1" hwp:rel-id="F2">figure 2</xref>). ABabDII mice were immunized at least twice with mutant peptides and IFNγ producing CD8+ T cells were monitored in ex vivo ICS analysis 7 days after the last immunization. CD8+ T cells were purified from spleen cell cultures of reactive mice using either IFNγ-capture or tetramer-guided FACSort. Sequencing of specific TCR α and β chain amplicons that were obtained by RACE-PCR revealed that this procedure yields an almost monoclonal CD8+ T cell population (not shown). In both cases, tested neo-antigen candidates lead to T cell reactivity, confirming not only predicted MHC binding by our pipeline but also immunogenicity in vivo in human TCR transgenic mice. Therefore this workflow also allows to generate potentially therapeutic relevant TCRs to be used in the clinics for cancer immunotherapy.</p><fig id="fig2" position="float" fig-type="figure" orientation="portrait" hwp:id="F2" hwp:rev-id="xref-fig-2-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389437v1/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2:</label><caption hwp:id="caption-3"><p hwp:id="p-20">Recognition of predicted epitopes by CD8+ T cells: Epitopes for recurrent mutations that have been identified <italic toggle="yes">i</italic> n silico to bind to HLA-A*02:01 using our pipeline were synthesized and used for immunization of human TCR transgenic ABabDII mice. Examples (RAC1:P29S and TRRAP:S722F) of ex vivo ICS analysis of mutant peptide immunized ABabDII mice 7 days after the last immunization are shown. Polyclonal stimulation with CD3/CD28 dynabeads was used as positive control, stimulation with an irrelevant peptide served as negative control (data not shown).</p></caption><graphic xlink:href="389437_fig2" position="float" orientation="portrait" hwp:id="graphic-3"/></fig></sec><sec id="s2e" hwp:id="sec-7"><title hwp:id="title-8">Recurrent neo-epitopes in patient populations</title><p hwp:id="p-21">Upon assumption of statistical independence, the product of the frequency of a recurrent neo-epitope with the frequency of class I alleles in the population and the incidence rates of cancer types provides an estimate for the number of patients that carry that specific neo-epitope. Using the number of newly diagnosed patients per year and HLA-1 frequency in the US population, we are able to compute the expected number of patients for 18 cancer entities for which both cancer census data and a TCGA study are available. The occurrence numbers for individual neo-epitope candidates range from 0 to 2,254 for PIK3CA:H1047R in breast cancer patients of type HLA-C*07:01; <xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-1" hwp:rel-id="T2">table 2</xref> presents a summary of expected patient numbers for the complete set of candidates. We estimate that the previously discussed RAC1:P29S is present in 628 patients with the HLA-A*02:01 allele per year in the US alone: in 556 melanoma patients and in 72 lung small cell, head &amp; neck or uterine carcinomas patients (see supplementary table 5 for details). For the CTNNB1:S33C variant, the total number of HLA-A*02:01 patients in the US is expected to be 364, from uterine corpus, prostate and liver cancer types. As another example, 115 myeloid leukemia patients in the US are expected to be of type HLA-A*02:01 and harbor the FLT3:D835Y variant.</p><table-wrap id="tbl2" orientation="portrait" position="float" hwp:id="T2" hwp:rev-id="xref-table-wrap-2-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389437v1/TBL2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T2</object-id><object-id pub-id-type="publisher-id">tbl2</object-id><label>Table 2:</label><caption hwp:id="caption-4"><p hwp:id="p-22">Expected number of newly diagnosed US patients by HLA-1 type and cancer entity. A) Expected number of patients of a given HLA-1 type who harbor at least one potentially immunogenic neo-epitope candidate for that HLA-1 type. Both the cancer incidence (<xref rid="c46" ref-type="bibr" hwp:id="xref-ref-46-1" hwp:rel-id="ref-46">46</xref>) and the allele frequency (<xref rid="c45" ref-type="bibr" hwp:id="xref-ref-45-1" hwp:rel-id="ref-45">45</xref>) are estimated for the US population. The probability that a patient harbors at least one variant from the set of neo-epitope candidates is computed using the assumption that the occurrence of variants in a cancer patient are statistically independent events. B) Number of neo-epitope candidates identified in the 18 studies shown in A, predicted to be a strong binder to the corresponding HLA-1 type.</p></caption><graphic xlink:href="389437_tbl2" position="float" orientation="portrait" hwp:id="graphic-4"/></table-wrap><p hwp:id="p-23"><xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 3</xref> shows the cumulative expected number of patients that carry a specific epitope, and with matching HLA-1 type, for the 50 candidates with the highest expected patients number. The number of patients is derived from the sum over all cancer entities, including those in which the candidate is not recurrent according to our criteria. For example, among newly diagnosed patients of type HLA-C*04:02, 88 prostate cancer patients are expected to carry the mutation PIK3CA:R88Q, even though its observed frequency in the PRAD study is as low as 0.2%.</p><fig id="fig3" position="float" fig-type="figure" orientation="portrait" hwp:id="F3" hwp:rev-id="xref-fig-3-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389437v1/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3:</label><caption hwp:id="caption-5"><p hwp:id="p-24">50 most frequent neo-epitope and HLA-1 combinations in patients for which strong MHC I binding is predicted: for each candidate, the expected number of patients is obtained by summing over the 18 cancer entities for which the number of newly diagnosed patients in the US is available, and for which a corresponding TCGA study has been included in our analysis.</p></caption><graphic xlink:href="389437_fig3" position="float" orientation="portrait" hwp:id="graphic-5"/></fig></sec></sec><sec id="s3" hwp:id="sec-8"><title hwp:id="title-9">Discussion</title><p hwp:id="p-25">Using existing cancer studies and neo-epitope binding predictions to MHC class I proteins, we propose a ranking of neo-epitopes that occur frequently in observed cancer patient cohorts, and that are potentially accessible to T cell immunotherapy treatments. This ranking is based on the expected number of patients of a particular HLA-1 type, who carry the recurrent mutation.</p><p hwp:id="p-26">Despite numerous mechanisms of immune evasion, neo-epitopes are important targets of endogenous immunity (<xref rid="c30" ref-type="bibr" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">30</xref>): in some cases at least, it has been shown that they contribute to tumor recognition (<xref rid="c31" ref-type="bibr" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref>), achieve high objective response (in melanoma, 32), and a single of them is presumably sufficient for tumor regression (<xref rid="c33" ref-type="bibr" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">33</xref>). Moreover, positive association has been shown between antigen load and cytolytic activity (<xref rid="c34" ref-type="bibr" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">34</xref>), activated T cells (<xref rid="c35" ref-type="bibr" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref>) and high levels of the PD-1 ligand (<xref rid="c36" ref-type="bibr" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref>). Taken together, these results suggest that neo-epitopes occupy a central role in regulating immune response to cancer, and that this role can be exploited for cancer immunotherapy.</p><p hwp:id="p-27">Targeting neo-epitopes based on non-recurrent, “private” somatic variants requires isolation of TCRs for each individual patient, which is currently still challenging (<xref rid="c37" ref-type="bibr" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref>). However, successful application of treatments based on genetically engineered lymphocytes has already been shown for epitopes arising from unmutated proteins (“public” epitopes): the MART-1 and gp100 proteins have been targeted in melanoma cases (<xref rid="c38" ref-type="bibr" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref>), as these proteins are expressed in the tumor cells. In another trial, Robbins et al. (<xref rid="c39" ref-type="bibr" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref>) have studied long-term follow-up of patients who were treated with TCR-transduced T cells against NY-ESO-1, a protein whose expression is normally restricted to testis, but which is frequently aberrantly expressed in tumor cells. The authors show that the treatment may be effective for some patients. These results show that immune treatments can be beneficial, even when the selected epitopes are not obtained from sequencing the patient's tumor, but originate from “off-the-shelf” peptides, whose sequence is known prior to the sequencing of the patient's tumor.</p><p hwp:id="p-28">However, targeting such unmutated epitopes presents safety and efficacy concerns (<xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-2" hwp:rel-id="ref-2">2</xref>): the administration of T cells transduced with MART-1 specific T-cell receptor have led to fatal outcomes (<xref rid="c40" ref-type="bibr" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref>), and cross-reactivity of TCR against MAGE-A3 (a protein normally restricted to testis and placenta) caused cardiovascular toxicity (<xref rid="c41" ref-type="bibr" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref>). Neo-epitopes based on recurrent somatic variants potentially alleviate such problems (as the target sequences are truly restricted to tumor cells), while retaining the benefits of “public” epitopes, for example regarding regulatory hurdles.</p><p hwp:id="p-29">The neo-epitope landscape is diverse and sparse (<xref rid="c33" ref-type="bibr" hwp:id="xref-ref-33-2" hwp:rel-id="ref-33">33</xref>), with few neo-epitopes that are both predicted strong binders and present in multiple patients. In their analysis, Hartmaier et al. (<xref rid="c13" ref-type="bibr" hwp:id="xref-ref-13-2" hwp:rel-id="ref-13">13</xref>) estimate that neo-epitopes suitable used for precision immuno-therapy might be relevant for about 0.3% of the population, in broad agreement with this study. However, the absolute number of patients is still considerable, even for neo-epitopes arising from less frequent mutations (between 1 and 3% of the cohort).</p><p hwp:id="p-30">Taking into account the fact that MHC binding is a necessary but not sufficient condition for T cell activity, and the limitations of MHC binding prediction algorithms, we provide an objective ranking of neo-epitopes based on recurrent variants, as a basis for the development of off-the-shelf immunotherapy treatments. We experimentally confirm T cell reactivity, thus immunogenicity, for a couple of these neo-epitopes.</p></sec><sec id="s4" hwp:id="sec-9"><title hwp:id="title-10">Methods</title><sec id="s4a" hwp:id="sec-10"><title hwp:id="title-11">Data Sets</title><p hwp:id="p-31">Somatic variants for different cancer entities have been determined using matched pairs of tumor and blood whole exome or whole genome sequencing in the TCGA consortium. We downloaded the open-access somatic variants from GDC data release 7.0, consisting of 33 TCGA projects and 10,182 donors in total from (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-2" hwp:rel-id="ref-14">14</xref>). We excluded patients without corresponding entries in the clinical information tables, and 7 projects with less than 100 samples, yielding 9,641 samples covering 26 cancer studies.</p></sec><sec id="s4b" hwp:id="sec-11"><title hwp:id="title-12">Variant Selection</title><p hwp:id="p-32">For each sample we selected all single nucleotide variants obtained by the “mutect2” pipeline, that had a “Variant_Type” equal to “SNP”, a valid ENSEMBL transcript ID and a valid protein mutation in “HGVSp_Short”. From these variants, we selected those with a “Variant_Classification” equal to “Missense_Mutation”. We checked that all variants had a “Mutation_Status” equal to (up to capitalisation) “Somatic”, that the total depth “t_depth” was the sum of the reference “t_ref_count” and the alternate “t_alt_count” alleles counts, and that the genomics variant length is one nucleotide. To avoid high number of false positives we consider only variants that are supported by at least 5 reads and have a VAF of at least 10%. Furthermore we removed any variant that occurs with more than 1% in any population contained in the ExAC database version 0.31 (<xref rid="c42" ref-type="bibr" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref>), by coordinates liftover from the GRCh38 to hg19 human genome versions. This way we obtained 26 cancer entity data sets containing a total of 9,641 samples with an overall 1,384,531 variants.</p></sec><sec id="s4c" hwp:id="sec-12"><title hwp:id="title-13">Recurrent Protein Variant Filtering</title><p hwp:id="p-33">We define recurrence strictly on the protein/amino acid exchange level, i.e. different nucleotide acid variants leading to the same amino acid exchange due to code redundancy will be counted together. Recurrent protein variants are defined within each TCGA study. A protein variant is deemed recurrent when it appears in at least 1% of all the patients in the cohort. As cancer types are only considered when the number of patients involved in the studies is greater than 100, this threshold ensures that every recurrent variant has been observed in at least 2 patients for a given cancer type. To be conservative, the recurrence frequency has been computed using, for the denominator, all patients with clinical information in the study, including those without high-confidence missense SNVs. Using this definition, the total number of recurrent amino acid changes is 1,055. A variant recurrent in multiple cancer types is counted multiple times in the above number, the number of unique recurrent variants regardless of the cancer is 869. Supplementary table 1 shows the most frequent amino acid exchanges across 25 cancer entities, as no variant from project TCGA-KIRC's donors is labeled as recurrent.</p><p hwp:id="p-34">Recurrent variants occurring at the same positions (for example when gene's IDH1 codon R132 is mutated to amino acid H, C, G or S) have been merged into 819 variants suitable for comparisons with the cancer hot spots lists (<xref rid="c10" ref-type="bibr" hwp:id="xref-ref-10-3" hwp:rel-id="ref-10">10</xref>). 122 out of the 819 merged variants belong to the set of 470 cancer hotspot variants, and 5 (PCBP1:L100, SPTLC3:R97, EEF1A1:T432, BCLAF1:E163 &amp; TTN:S3271) to the set of presumptive false positives hotspots listed in the supplementary material of (<xref rid="c10" ref-type="bibr" hwp:id="xref-ref-10-4" hwp:rel-id="ref-10">10</xref>).</p></sec><sec id="s4d" hwp:id="sec-13"><title hwp:id="title-14">Epitopes Selection and MHC Class I Binding Prediction</title><p hwp:id="p-35">In the next step all peptide stretches (9-, 10, or 11-mers) containing any of the identified recurrent amino acid exchanges are generated in silico. For MHC class I binding prediction we selected 11 frequent HLA-1 types: HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, HLA-B*07:02, HLA-B*15:01, HLA-C*04:01, HLA-C*07:02, HLA-A*01:01, HLA-B*08:01, HLA-C*06:02, HLA-C*07:01. We predicted the MHC class I binding using NetMHCcons (<xref rid="c43" ref-type="bibr" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref>) v1.1, which predicts peptides IC50 binding, and classifies these predictions as non-binder, weak and strong binders. In the study, we have used these classes to filter our neo-epitope candidate.</p><p hwp:id="p-36">For a given recurrent variant and a given HLA-1 type, the epitope prediction pipeline can produce multiple overlapping epitopes candidates, differing only by their length. To remove such size redundancy, only the epitope with the lowest predicted mutant sequence IC50 is retained. This procedure also removes non-overlapping epitopes, to keep only at most one epitope per recurrent protein variant, cancer type and HLA-1 type. For comparison we also compute the IC50 for the respective wild type peptide.</p><p hwp:id="p-37">This way, we obtain 769 strong binding recurrent peptides and 1829 weak binders. Their complete list is in supplementary table 2, where each candidate is listed with the HLA-1 type it is preticted to bind to.</p></sec><sec id="s4e" hwp:id="sec-14"><title hwp:id="title-15">Data QC</title><p hwp:id="p-38">To ensure that the proportion of variants caused by technical artifacts is small, we have computed the proportion of SNVs called in poly-A, poly-C, poly-G or poly-T repeats of length greater than 6 have been computed for each data study (<xref rid="c44" ref-type="bibr" hwp:id="xref-ref-44-1" hwp:rel-id="ref-44">44</xref>), for unique variants (that occur in only one patient across a project cohort), and for variants that are observed more than once in a cohort (supplementary figure 1). For comparison, we have computed the expected frequency of such events, assuming that all possible 11-mers (the mutated nucleotide at the center, flanked by 5 nucleotides on each side) are equiprobable, regardless of their sequence.</p></sec><sec id="s4f" hwp:id="sec-15"><title hwp:id="title-16">Generation of mutation-specific T cells in ABabDII mice</title><p hwp:id="p-39">For immunisation 8-12-week old ABabDII mice were injected subcutaneously with 100 μg of mutant short peptide (9-10mers, JPT) supplemented with 50 μg CpG 1826 (TIB Molbiol), emulsified in incomplete Freund’s adjuvant (Sigma). Repetitive immunizations were performed with the same mixture at least three weeks apart. Mutation-specific CD8+ T cells in the peripheral blood of immunized animals were assessed by intracellular cytokine staining (ICS) for IFNγ 7 days after each boost. All animal experiments were performed according to institutional and national guidelines and regulations after approval by the governmental authority (Landesamt für Gesundheit und Soziales, Berlin).</p></sec><sec id="s4g" hwp:id="sec-16"><title hwp:id="title-17">Patient Number Estimates and HLA-1 Frequencies</title><p hwp:id="p-40">HLA-1 frequency data f for the U.S. population was retrieved from the Allele Frequency Net Database (AFND) (<xref rid="c45" ref-type="bibr" hwp:id="xref-ref-45-2" hwp:rel-id="ref-45">45</xref>). Frequency data were estimated by averaging the allele frequencies* of multiple population datasets from the North American (NAM) geographical region. The major U.S. ethnic groups were included and sampled under the NAM category.</p><p hwp:id="p-41">Cancer incidence data for the U.S. population (<italic toggle="yes">N<sub>d</sub></italic>) was retrieved from the GLOBOCAN 2012 project of the International Agency for Research on Cancer, WHO (<xref rid="c46" ref-type="bibr" hwp:id="xref-ref-46-2" hwp:rel-id="ref-46">46</xref>).</p><p hwp:id="p-42">We assume that the fraction of a recurrent variant in the U.S. population affected by cancer entity <italic toggle="yes">d</italic> (<italic toggle="yes">r<sub>d</sub></italic>) is identical to the observed ratio of that variant in the corresponding TCGA study.</p><p hwp:id="p-43">Given a variant leading to a neo-epitope predicted to be binding strongly to MHC class I proteins of HLA-1 type <italic toggle="yes">h</italic>, the number of patients of HLA-1 type <italic toggle="yes">h</italic> whose tumor contain that variant is expected to be</p><disp-formula hwp:id="disp-formula-1">
<alternatives hwp:id="alternatives-1"><graphic xlink:href="389437_ueqn1.gif" position="float" orientation="portrait" hwp:id="graphic-6"/></alternatives>
</disp-formula><p hwp:id="p-44">The summation runs over 18 diseases <italic toggle="yes">d</italic> for which both the TCGA projects and the cancer incidence data are available.</p></sec></sec></body><back><ref-list hwp:id="ref-list-1"><title hwp:id="title-18">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Schumacher T. N."><surname>Schumacher</surname>, <given-names>T. N.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Schreiber R. D."><surname>Schreiber</surname>, <given-names>R. D.</given-names></string-name> <article-title hwp:id="article-title-2">Neoantigens in cancer immunotherapy</article-title>. <source hwp:id="source-1">Science</source> <volume>348</volume>, <fpage>69</fpage>–<lpage>74</lpage> (<year>2015</year>).</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1 xref-ref-2-2"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Blankenstein T."><surname>Blankenstein</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Leisegang M."><surname>Leisegang</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Uckert W."><surname>Uckert</surname>, <given-names>W.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Schreiber H."><surname>Schreiber</surname>, <given-names>H.</given-names></string-name> <article-title hwp:id="article-title-3">Targeting cancer-specific mutations by T cell receptor gene therapy</article-title>. <source hwp:id="source-2">Curr. Opin. Immunol</source>. <volume>33</volume>, <fpage>112</fpage>–<lpage>119</lpage> (<year>2015</year>).</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Rosenberg S. A."><surname>Rosenberg</surname>, <given-names>S. A.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Restifo N. P."><surname>Restifo</surname>, <given-names>N. P.</given-names></string-name> <article-title hwp:id="article-title-4">Adoptive cell transfer as personalized immunotherapy for human cancer</article-title>. <source hwp:id="source-3">Science</source> <volume>348</volume>, <fpage>62</fpage>–<lpage>8</lpage> (<year>2015</year>).</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Wirth T. C."><surname>Wirth</surname>, <given-names>T. C.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Kühnel F."><surname>Kühnel</surname>, <given-names>F.</given-names></string-name> <article-title hwp:id="article-title-5">Neoantigen Targeting - Dawn of a New Era in Cancer Immunotherapy?</article-title> <source hwp:id="source-4">Front. Immunol.</source> <volume>8</volume>, <fpage>1848</fpage> (<year>2017</year>).</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Engels B."><surname>Engels</surname>, <given-names>B.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-6">Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity</article-title>. <source hwp:id="source-5">Cancer Cell</source> <volume>23</volume>, <fpage>516</fpage>–<lpage>526</lpage> (<year>2013</year>).</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Snyder A."><surname>Snyder</surname>, <given-names>A.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Chan T. A."><surname>Chan</surname>, <given-names>T. A.</given-names></string-name> <article-title hwp:id="article-title-7">Immunogenic peptide discovery in cancer genomes</article-title>. <source hwp:id="source-6">Curr. Opin. Genet. Dev</source>. <volume>30</volume>, <fpage>7</fpage>–<lpage>16</lpage> (<year>2015</year>).</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Vita R."><surname>Vita</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-8">The immune epitope database (IEDB) 3.0</article-title>. <source hwp:id="source-7">Nucleic. Acids Res</source>. <volume>43</volume>, <fpage>D405</fpage>–<lpage>D412</lpage> (<year>2015</year>).</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Leisegang M."><surname>Leisegang</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-9">Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation</article-title>. <source hwp:id="source-8">Clin. Cancer Res</source>. <volume>22</volume>, <fpage>2734</fpage>–<lpage>43</lpage> (<year>2016</year>).</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Li F."><surname>Li</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-10">Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination</article-title>. <source hwp:id="source-9">Oncoimmunology</source>. <volume>5</volume>, <fpage>e1238539</fpage> (<year>2016</year>).</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1 xref-ref-10-2 xref-ref-10-3 xref-ref-10-4"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Chang M. T."><surname>Chang</surname>, <given-names>M. T.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-11">Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity</article-title>. <source hwp:id="source-10">Nat. Biotech</source>. <volume>34</volume>, <fpage>155</fpage>–<lpage>163</lpage> (<year>2016</year>).</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Martincorena I."><surname>Martincorena</surname>, <given-names>I.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-12">Universal Patterns of Selection in Cancer and Somatic Tissues</article-title>. <source hwp:id="source-11">Cell</source> <volume>171</volume>, <fpage>1029</fpage>–<lpage>1041.e21</lpage> (<year>2017</year>).</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Warren R.L."><surname>Warren</surname>, <given-names>R.L.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Holt R.A."><surname>Holt</surname>, <given-names>R.A.</given-names></string-name> <article-title hwp:id="article-title-13">A census of predicted mutational epitopes suitable for immunologic cancer control</article-title>. <source hwp:id="source-12">Human Immunology</source> <volume>71</volume> <fpage>245</fpage>-<lpage>254</lpage> (<year>2010</year>).</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1 xref-ref-13-2"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Hartmaier R. J."><surname>Hartmaier</surname>, <given-names>R. J.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-14">Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies</article-title>. <source hwp:id="source-13">Genome Medi</source>. <volume>9</volume>, <fpage>16</fpage> (<year>2017</year>).</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1 xref-ref-14-2"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Grossman R. L."><surname>Grossman</surname>, <given-names>R. L.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-15">Toward a Shared Vision for Cancer Genomic Data</article-title>. <source hwp:id="source-14">N. Engl. J. Medi</source>. <volume>375</volume>, <fpage>1109</fpage>–<lpage>1112</lpage> (<year>2016</year>).</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1 xref-ref-15-2"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Fritsch E. F."><surname>Fritsch</surname>, <given-names>E. F.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-16">HLA-binding properties of tumor neoepitopes in humans</article-title>. <source hwp:id="source-15">Cancer Immunol. Res</source>. <volume>2</volume>, <fpage>522</fpage>–<lpage>9</lpage> (<year>2014</year>).</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1 xref-ref-16-2"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Van Buuren M. M."><surname>Van Buuren</surname>, <given-names>M. M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Calis J. J."><surname>Calis</surname>, <given-names>J. J.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Schumacher T. N."><surname>Schumacher</surname>, <given-names>T. N.</given-names></string-name> <article-title hwp:id="article-title-17">High sensitivity of cancer exome-based CD8 T cell neo-antigen identification</article-title>. <source hwp:id="source-16">Oncoimmunology</source>. <volume>3</volume>, <fpage>e28836</fpage> (<year>2014</year>).</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Wölfel T"><surname>Wölfel</surname>, <given-names>T</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-18">A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma</article-title>. <source hwp:id="source-17">Science</source> <volume>269</volume>, <fpage>1281</fpage>–<lpage>4</lpage> (<year>1995</year>).</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Landsberg J."><surname>Landsberg</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-19">Autochthonous primary and metastatic melanomas in Hgf-Cdk4R24C mice evade T-cell-mediated immune surveillance</article-title>. <source hwp:id="source-18">Pigment Cell Melanoma Res</source>. <volume>23</volume>, <fpage>649</fpage>–<lpage>660</lpage> (<year>2010</year>).</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1"><label>19.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Platz A."><surname>Platz</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ringborg U."><surname>Ringborg</surname>, <given-names>U.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Hansson J."><surname>Hansson</surname>, <given-names>J.</given-names></string-name> <article-title hwp:id="article-title-20">Hereditary cutaneous melanoma</article-title>. <source hwp:id="source-19">Semin. Cancer Biol</source>. <volume>10</volume>, <fpage>319</fpage>–<lpage>326</lpage> (<year>2000</year>).</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1 xref-ref-20-2"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Vogelstein B."><surname>Vogelstein</surname>, <given-names>B.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-21">Cancer genome landscapes</article-title>. <source hwp:id="source-20">Science</source> <volume>339</volume>, <fpage>1546</fpage>–<lpage>58</lpage> (<year>2013</year>).</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Rubio-Perez C."><surname>Rubio-Perez</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-22">In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities</article-title>. <source hwp:id="source-21">Cancer Cell</source> <volume>27</volume>, <fpage>382</fpage>–<lpage>396</lpage> (<year>2015</year>).</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Vu H. L."><surname>Vu</surname>, <given-names>H. L.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rosenbaum S."><surname>Rosenbaum</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Purwin T. J."><surname>Purwin</surname>, <given-names>T. J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Davies M. A."><surname>Davies</surname>, <given-names>M. A.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Aplin A. E."><surname>Aplin</surname>, <given-names>A. E.</given-names></string-name> <article-title hwp:id="article-title-23">RAC1 P29S regulates PD-L1 expression in melanoma</article-title>. <source hwp:id="source-22">Pigment Cell Melanoma Res</source>. <volume>28</volume>, <fpage>590</fpage>–<lpage>598</lpage> (<year>2015</year>).</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Austinat M."><surname>Austinat</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-24">Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma</article-title>. <source hwp:id="source-23">Mol. Cancer</source> <volume>7</volume>, <fpage>21</fpage> (<year>2008</year>).</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1"><label>24.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Pai S. G."><surname>Pai</surname>, <given-names>S. G.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-25">Wnt/beta-catenin pathway: modulating anticancer immune response</article-title>. <source hwp:id="source-24">J. Hematol. Oncol.</source> <volume>10</volume>, <fpage>101</fpage> (<year>2017</year>).</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Spranger S."><surname>Spranger</surname>, <given-names>S.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Gajewski T. F."><surname>Gajewski</surname>, <given-names>T. F.</given-names></string-name> <article-title hwp:id="article-title-26">A new paradigm for tumor immune escape: β-catenin-driven immune exclusion</article-title>. <source hwp:id="source-25">J. Immunotherapy Cancer</source> <volume>3</volume>, <fpage>43</fpage> (<year>2015</year>).</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Cho J."><surname>Cho</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-27">Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma</article-title>. <source hwp:id="source-26">Clin. Transl. Oncol</source>. <volume>19</volume>, <fpage>1247</fpage>–<lpage>1252</lpage> (<year>2017</year>).</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Reiter K"><surname>Reiter</surname>, <given-names>K</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-28">Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia</article-title>. <source hwp:id="source-27">Leukemia</source> <volume>32</volume>, <fpage>313</fpage>–<lpage>322</lpage> (<year>2018</year>).</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1"><label>28.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Li L.-P."><surname>Li</surname>, <given-names>L.-P.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-29">Transgenic mice with a diverse human T cell antigen receptor repertoire</article-title>. <source hwp:id="source-28">Nat. Med</source>. <volume>16</volume>, <fpage>1029</fpage>–<lpage>1034</lpage> (<year>2010</year>).</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1"><label>29.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Li L."><surname>Li</surname>, <given-names>L.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Blankenstein T."><surname>Blankenstein</surname>, <given-names>T.</given-names></string-name> <article-title hwp:id="article-title-30">Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplastembryonic stem cell fusion</article-title>. <source hwp:id="source-29">Nat. Prot</source>. <volume>8</volume>, <fpage>1567</fpage>–<lpage>1582</lpage> (<year>2013</year>).</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1"><label>30.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Bethune M. T."><surname>Bethune</surname>, <given-names>M. T.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Joglekar A. V."><surname>Joglekar</surname>, <given-names>A. V.</given-names></string-name> <article-title hwp:id="article-title-31">Personalized T cell-mediated cancer immunotherapy: progress and challenges</article-title>. <source hwp:id="source-30">Curr. Opini. Biotech</source>. <volume>48</volume>, <fpage>142</fpage>–<lpage>152</lpage> (<year>2017</year>).</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><label>31.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Robbins P. F."><surname>Robbins</surname>, <given-names>P. F.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-32">Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells</article-title>. <source hwp:id="source-31">Nat. Med</source>. <volume>19</volume>, <fpage>747</fpage>–<lpage>52</lpage> (<year>2013</year>).</citation></ref><ref id="c32" hwp:id="ref-32"><label>32.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Rosenberg S. A."><surname>Rosenberg</surname>, <given-names>S. A.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Dudley M. E."><surname>Dudley</surname>, <given-names>M. E.</given-names></string-name> <article-title hwp:id="article-title-33">Adoptive cell therapy for the treatment of patients with metastatic melanoma</article-title>. <source hwp:id="source-32">Curr. Opini. Immunol</source>. <volume>21</volume>, <fpage>233</fpage>–<lpage>240</lpage> (<year>2009</year>).</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1 xref-ref-33-2"><label>33.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Tran E."><surname>Tran</surname>, <given-names>E.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-34">Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer</article-title>. <source hwp:id="source-33">Science</source> <volume>344</volume>, <fpage>641</fpage>–<lpage>5</lpage> (<year>2014</year>).</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1"><label>34.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Rooney M."><surname>Rooney</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shukla S."><surname>Shukla</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wu C."><surname>Wu</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Getz G."><surname>Getz</surname>, <given-names>G.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Hacohen N."><surname>Hacohen</surname>, <given-names>N.</given-names></string-name> <article-title hwp:id="article-title-35">Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity</article-title>. <source hwp:id="source-34">Cell</source> <volume>160</volume>, <fpage>48</fpage>–<lpage>61</lpage> (<year>2015</year>).</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1"><label>35.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.35" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Charoentong P."><surname>Charoentong</surname>, <given-names>P.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-36">Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade</article-title>. <source hwp:id="source-35">Cell Reports</source> <volume>18</volume>, <fpage>248</fpage>–<lpage>262</lpage> (<year>2017</year>).</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><label>36.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.36" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="McGranahan N."><surname>McGranahan</surname>, <given-names>N.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-37">Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</article-title>. <source hwp:id="source-36">Science</source> <volume>351</volume>, <fpage>1463</fpage>–<lpage>9</lpage> (<year>2016</year>).</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1"><label>37.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Strønen E."><surname>Strønen</surname>, <given-names>E.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-38">Targeting of cancer neoantigens with donor-derived T cell receptor repertoires</article-title>. <source hwp:id="source-37">Science</source> <volume>352</volume>, <fpage>1337</fpage>–<lpage>41</lpage> (<year>2016</year>).</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1"><label>38.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Johnson L. A."><surname>Johnson</surname>, <given-names>L. A.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-39">Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen</article-title>. <source hwp:id="source-38">Blood</source> <volume>114</volume>, <fpage>535</fpage>–<lpage>46</lpage> (<year>2009</year>).</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1"><label>39.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Robbins P. F."><surname>Robbins</surname>, <given-names>P. F.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-40">A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response</article-title>. <source hwp:id="source-39">Clin. Cancer. Res</source>. <volume>21</volume>, <fpage>1019</fpage>–<lpage>27</lpage> (<year>2015</year>).</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1"><label>40.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.40" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Van den Berg J. H."><surname>Van den Berg</surname>, <given-names>J. H.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-41">Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor</article-title>. <source hwp:id="source-40">Mol. Ther</source>. <volume>23</volume>, <fpage>1541</fpage>–<lpage>1550</lpage> (<year>2015</year>).</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label>41.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.41" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Linette G. P."><surname>Linette</surname>, <given-names>G. P.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-42">Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma</article-title>. <source hwp:id="source-41">Blood</source> <volume>122</volume>, <fpage>863</fpage>–<lpage>71</lpage> (<year>2013</year>).</citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1"><label>42.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Lek M."><surname>Lek</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-43">Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source hwp:id="source-42">Nature</source> <volume>536</volume>, <fpage>285</fpage>–<lpage>291</lpage> (<year>2016</year>).</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1"><label>43.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.43" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Karosiene E."><surname>Karosiene</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lundegaard C."><surname>Lundegaard</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lund O."><surname>Lund</surname>, <given-names>O.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Nielsen M."><surname>Nielsen</surname>, <given-names>M.</given-names></string-name> <article-title hwp:id="article-title-44">NetMHCcons: a consensus method for the major histocompatibility complex class I predictions</article-title>. <source hwp:id="source-43">Immunogenetics</source> <volume>64</volume>, <fpage>177</fpage>–<lpage>186</lpage> (<year>2012</year>).</citation></ref><ref id="c44" hwp:id="ref-44" hwp:rev-id="xref-ref-44-1"><label>44.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.44" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-44"><string-name name-style="western" hwp:sortable="Laehnemann D."><surname>Laehnemann</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Borkhardt A."><surname>Borkhardt</surname>, <given-names>A.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="McHardy A. C."><surname>McHardy</surname>, <given-names>A. C.</given-names></string-name> <article-title hwp:id="article-title-45">Denoising DNA deep sequencing datahigh-throughput sequencing errors and their correction</article-title>. <source hwp:id="source-44">Brief. Bioinform</source>. <volume>17</volume>, <fpage>154</fpage>–<lpage>179</lpage> (<year>2016</year>).</citation></ref><ref id="c45" hwp:id="ref-45" hwp:rev-id="xref-ref-45-1 xref-ref-45-2"><label>45.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.45" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-45"><string-name name-style="western" hwp:sortable="González-Galarza F."><surname>González-Galarza</surname>, <given-names>F.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-46">Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations</article-title>. <source hwp:id="source-45">Nucleic. Acids Res</source>. <volume>43</volume>, <fpage>D784</fpage>–<lpage>D788</lpage> (<year>2015</year>).</citation></ref><ref id="c46" hwp:id="ref-46" hwp:rev-id="xref-ref-46-1 xref-ref-46-2"><label>46.</label><citation publication-type="journal" citation-type="journal" ref:id="389437v1.46" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-46"><string-name name-style="western" hwp:sortable="Ferlay J."><surname>Ferlay</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-47">Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012</article-title>. <source hwp:id="source-46">Int. J. Cancer</source> <volume>136</volume>, <fpage>E359</fpage>–<lpage>E386</lpage> (<year>2015</year>).</citation></ref></ref-list></back></article>
